Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872812 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18305953 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27620763 | 0.80 | CYP4F2 (0.38) | LMNAMAOASLC6A2 | |
| SCHEMBL27471772 | 0.80 | MAPK1 (0.37) | LMNAMAOASLC6A2 | |
| SCHEMBL27377752 | 0.80 | MAPK1 (0.37) | LMNAMAOASLC6A2 | |
| SCHEMBL23227487 | 0.78 | — | — | |
| SCHEMBL25528898 | 0.78 | — | — | |
| SCHEMBL30112670 | 0.77 | HPGD (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27602108 | 0.76 | NAAA (0.43) | — | |
| SCHEMBL4409122 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949562-B | Positive allosteric modulators of muscarinic M2 receptors | 拜耳制药股份公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3307741-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198342-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | CHRNB2 27/4885CHRNA4 15/4885CHRNB4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.